Business
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210US $15M milestone payment from Merck extends company’s cash runway to Q3 2026Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is pl
About this update from Neuphoria Therapeutics Inc.
[{"type":"image","alt":"Neuphoria Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neuphoria Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":134,"url":"https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mnUSgCG0WTU8RlTRZzCzeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361","width":300,"height":134}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"US $15M milestone payment from Merck extends company’s cash runway to Q3 2026","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is planned to follow the read-out of the Phase 3 study in social anxiety disorder SAD.","length":185,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":581,"olType":false},{"type":"text","content":"BURLINGTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provided a review of 2024 and highlighted plans for 2025.","length":295,"tagName":"p"},{"type":"text","content":"“2024 and the first quarter of 2025 were transformational for our pipeline; Our internal BNC210 program entered Ph3 in Social Anxiety Disorder with robust enrollment, and our partnered α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM) program with Merck for the treatment of the symptoms of Alzheimer’s disease dementia advanced to Phase 2,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. “We are now beginning a promising 2025 as we look to deploy our resources on programs that have the ...